<DOC>
	<DOCNO>NCT00001611</DOCNO>
	<brief_summary>This study investigate whether medication cytomegalovirus ( CMV ) retinitis-a viral infection eye-can safely stop HIV-infected patient whose immune function improve anti-HIV therapy . Medicines take fight CMV infection ( ganciclovir , foscarnet , cidofovir ) cause serious side effect , low blood count kidney damage . Stopping medication may , therefore , beneficial . Patients HIV infection develop CVM retinitis usually low level infection-fighting white blood cell call CD4 cells-less 50 cell per microliter blood . New anti-HIV medication able raise CD4 level improve immune function many patient . This study see patient CD4 level 150 cell per microliter fight CVM retinitis without additional anti-CVM drug . HIV-infected patient CVM retinitis physical examination complete eye examination . These test repeat 2 week . If evidence CMV infection progress , location immediately sight-threatening , anti-CMV medication stop . Patients examine every 2 week 3 month every 3 week next 3 month . Patients whose CD4 count remain 100 6 month continue follow every 4 week CVM infection become active . At time , anti-CVM medicine re-started . Patients also blood urine sample take test level HIV CMV blood urine , interview vision affect daily activity .</brief_summary>
	<brief_title>Immune Activity Against CVM Retinitis</brief_title>
	<detailed_description>This clinical trial determine whether elevated CD4 count result medication human immunodeficiency virus ( HIV ) effective control cytomegalovirus ( CMV ) retinitis . Patients non-progressive retinal disease consistent inactive CMV retinitis location immediately sight threaten , currently receive systemic maintenance therapy ganciclovir , foscarnet , cidofovir , total CD4 cell count great 150 cell per microliter anti-CMV therapy discontinue . Patients closely follow progression CMV retinitis . The primary endpoint study progression CMV retinitis . Secondary endpoint include occurrence extraocular CMV disease , morbidity , mortality , virologic data , HIV burden .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis AIDS define Centers Disease Control . Inactive , nonsightthreatening CMV retinitis . Non sightthreatening CMV retinitis define CMV retinitis within 1000 micron optic disc 1000 micron fovea . Exception : patient CMV retinitis within 1000 micron fovea disc one eye , visual acuity eye bad 20/400 without use eccentric fixation , visual acuity eye 20/400 good . CD4 T cell count great 150 cell per microliter . Patients must able understand nature study , agree provision , understand sign inform consent form . Women men age 18 old eligible enrollment . Platelets great 25,000/microliter . Hemoglobin great 8.5 gm . Total neutrophil count great 750/mm ( 3 ) . Karnofsky performance score great equal 60 . Receiving systemic antiCMV therapy . Receiving antiHIV therapy . If patient receive IL2 , least one month last infusion must elapse prior assessment eligibility . EXCLUSION CRITERIA : Intraocular sustain release ganciclovir implant eye le 9 month , organ involvement CMV infection require use systemic ganciclovir foscarnet . CMV retinitis involve retina solely anterior equator , within 1000 micron optic disc , within 1000 micron fovea . Exception : patient lesion involve fovea disc cause visual acuity bad 20/400 without use eccentric fixation , may include . Opacification cornea , lens , vitreous either eye precludes examination fundus . Other retinal disease could obscure diagnosis CMV retinitis , ocular toxoplasmosis . Significant psychiatric emotional disorder would impair patient understand participation trial . Life expectancy less three month . Active CMV disease require systemic antiCMV therapy . CMV retinitis first diagnosised CD4 Tcell count great 150 cell per microliter . Need medication antiCMV effect . Participation conflict clinical trial . Progression CMV retinitis screen baseline examination .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>AIDS</keyword>
	<keyword>Eye</keyword>
	<keyword>Treatment</keyword>
	<keyword>Opportunistic Infection</keyword>
	<keyword>Immunology</keyword>
	<keyword>Retinitis</keyword>
</DOC>